 Connection
Michael Bristow to Vasodilator Agents
This is a "connection" page, showing publications Michael Bristow has written about Vasodilator Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.017 |
|
|
|
-
Bristow MR. Polymorphic variation in the G-protein beta-3 subunit gene and response to BiDil in A-HeFT: Basis for an African-American pharmacogenetic advantage to nitric oxide donor therapy? JACC Heart Fail. 2014 Dec; 2(6):558-60.
Score: 0.404
-
Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ. The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol. 1998 Dec; 21(12 Suppl 1):I3-13.
Score: 0.134
-
Bristow MR, Larrabee P, M?ller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Investig. 1992; 70 Suppl 1:S105-13.
Score: 0.083
-
Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD, M?ller-Beckmann B. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 1992; 19 Suppl 1:S68-80.
Score: 0.083
-
Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990 Mar; 88(3):223-9.
Score: 0.073
-
MacGregor JF, Wachter SB, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail. 2009 Jan-Feb; 15(1):5-8.
Score: 0.068
-
Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, Sageman WS, Daniels JR. Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab Invest. 1981 Aug; 45(2):157-68.
Score: 0.040
-
Loh E, Elkayam U, Cody R, Bristow M, Jaski B, Colucci WS. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail. 2001 Jun; 7(2):114-21.
Score: 0.040
-
Schleman KA, Lindenfeld JA, Lowes BD, Bristow MR, Ferguson D, Wolfel EE, Abraham WT, Zisman LS. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail. 2001 Mar; 7(1):4-12.
Score: 0.039
-
Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, Bristow MR. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest. 1995 Dec; 108(6):1524-32.
Score: 0.027
-
Hershberger RE, Feldman AM, Bristow MR. A1-adenosine receptor inhibition of adenylate cyclase in failing and nonfailing human ventricular myocardium. Circulation. 1991 Apr; 83(4):1343-51.
Score: 0.020
-
Bristow M. Vasodilation in treatment of hypertension. N Engl J Med. 1970 May 07; 282(19):1102.
Score: 0.005
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|